中药口服液治疗缺血性心脑血管病血瘀证心率变异性异常的临床研究

Clinical Observation on Treatment of Heart Rate Variability of Blood Stasis of Ischemic Cardio-cerebral Vascular Diseases with Chinese Medicine Oral Fluid

目的:探讨中药制剂治疗缺血性心脑血管病血瘀证心率变异性异常患者的临床疗效和安全性。方法:采用循证医学的方法。185例患者按临床随机分为A、B、C、D、E5组,分别服用抗栓1、2、3、4、5号口服液3个月。结果:在缓解心绞痛、TCD、心电图、血瘀证、脑影像学和血液流变学疗效总有效率方面,A、B、C组明显优于D组、E组(P<0.01或P<0.001);A、B、C组之间比较无显著性差异。结论:治疗缺血性心脑血管病血瘀证心率变异性异常患者的疗效,以A组(江医14号)、C组(江医2号)和B组(阳性对照药利脑心胶囊)最优,D组(江医37号)次之,E组(安慰剂二陈汤)最差(P<0.05～0.001)。各药均安全无毒。

Objective：To probe the therapeutic effect and safety of Chinese medicines for heart rate variability of blood stasis of ischemic cardio-cerebral vascular diseases. Methods： The method of evidencebased medicine （EBM） was adopted. The 185 patients were randomized into Group A,B,O,D,and E and administered Kangshuan （anti-embolus） 1,2,3,4, and 5 Oral Fluid respectively for 3 months. Results： In relieving angina pectoris and in the aspects of transcranial doppler （TOD）, electrocardiogram （ECG）, blood stasis, hemorheology,and brain image, the total effective rate of Group A, B and O was obviously better than that of Group D and E （ P〈0.01 or P〈0. 001 ） ,and there was no significant difference among GroupA, B and C. Conclusion： For the heart rate variability of blood stasis of ischemic cardio-cerebral vascular diseases, the effect of Group A （Jiangyi No. 14）,Group O （Jiangyi No. 2）,and Group B （Linaoxin Capsule,the medicine for comparison） is the best, Group D （Jiangyi No. 37） takes second place, and Group E （placebo,Erchen Tang） is the last （P〈0.05-0. 001）. All of them are safe,without toxicity.